サンプル依頼リスト カート
  • English
  • Korean
市場調査レポート
商品コード
1363792

二重特異性抗体の世界市場規模調査＆予測、適応症別、地域別分析、2023-2030年

Global Bispecific Antibodies Market Size Study & Forecast, by Indication (Cancer, Inflammatory & Autoimmune Disorders, Others), and Regional Analysis, 2023-2030

出版日
ページ情報
英文
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
二重特異性抗体の世界市場規模調査＆予測、適応症別、地域別分析、2023-2030年
出版日: 2023年10月04日
発行: Bizwit Research & Consulting LLP
ページ情報: 英文
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の二重特異性抗体市場は、2022年に約57億3,000万米ドルと評価され、予測期間2023年から2030年にかけて44.0％以上の健全な成長率で成長すると予測されています。

二特異性抗体は、2つの異なる標的分子に同時に結合するように作られた治療用タンパク質の一種です。これらの抗体は、遺伝子工学的手法により、異なる抗原またはレセプターを認識する2つの別々の抗原結合部位を有しています。二特異性抗体は、2つの異なる標的分子に結合することで、これらの分子を組み立てたり、相互作用を制御したり、あるいは体の部位に薬効物質を運搬したりします。二特異性抗体は、通常単一の標的に結合する従来のモノクローナル抗体と比較して、いくつかの利点があります。二重特異性抗体は、多数の疾患関連経路を同時に標的としたり、免疫細胞を健康な組織から腫瘍細胞へと誘導するために使用されます。標的療法や個別化療法への需要の高まり、抗体工学技術の著しい進歩、国内外の利害関係者間の共同研究やパートナーシップの増加が、推定期間中の市場需要を促進している主な要因です。

加えて、がん患者の急増は、免疫チェックポイント阻害剤やT細胞エンゲイジャーとして設計されたものを中心とする生物特異的抗体を含む様々な代替治療への需要を煽り、ひいては世界全体の市場成長を加速させています。The Global Cancer Observatory（GCO）によると、2020年には世界中で約1,930万人のがん患者が新たに報告され、この数は2040年には3,020万人に増加すると予想されています。生物特異的抗体は、腫瘍細胞を攻撃するよう免疫細胞を誘導し、腫瘍の退縮と患者の転帰の改善をもたらします。さらに、生物学的製剤の研究開発への投資の増加や、バイオ医薬品のパイプラインの堅調な成長は、予測期間中に様々な有利な機会をもたらします。しかし、複雑な市場開拓と製造、規制上の課題が、2023-2030年の予測期間を通じて市場成長に課題しています。

二重特異性抗体の世界市場調査において考慮した主要地域は、アジア太平洋、北米、欧州、ラテンアメリカ、中東・アフリカです。北米は、規制当局による二重特異性抗体の承認の増加、研究開発活動への投資の増加、いくつかの主要な市場プレイヤーの存在により、2022年の市場を独占しました。例えば、2022年10月に初の二重特異性B細胞成熟抗原であるteclistamab-cqyv（Tecvayli、Janssen Biotech, Inc.）がFDAの承認を取得しました。さらに、二重特異性抗体を創製するために、補完的な科学的専門知識や技術を利用するためのパートナーシップや共同研究に参加する企業も増えています。こうしたパートナーシップは研究開発のイニシアチブを促進し、市場拡大をさらに加速させています。欧州は予測期間中に大幅なCAGRで成長すると予想されています。二重特異性抗体の需要の急増、技術的進歩への注目の高まり、国内外の利害関係者間の共同研究やパートナーシップの増加が、同地域全体の市場需要を大きく促進しています。

本調査の目的は、近年における様々なセグメントと国の市場規模を明らかにし、今後数年間の市場規模を予測することです。本レポートは、調査対象国における産業の質的・量的側面を盛り込むよう設計されています。

また、市場の将来的な成長を規定する促進要因や課題などの重要な側面に関する詳細情報も提供しています。さらに、主要企業の競合情勢や製品提供の詳細な分析とともに、利害関係者が投資するためのミクロ市場における潜在的な機会も組み込んでいます。.

目次

第1章 エグゼクティブサマリー

第2章 世界の二重特異性抗体市場の定義と範囲

  • 調査目的
  • 市場の定義と範囲
    • 産業の進化
    • 調査範囲
  • 調査対象年
  • 通貨換算レート

第3章 二重特異性抗体の世界市場力学

  • 二重特異性抗体市場の影響分析（2020-2030年）
    • 市場促進要因
      • 標的治療および個別化治療に対する需要の増加
      • がん患者の急増
    • 市場の課題
      • 複雑な開発と製造
      • 規制上の課題
    • 市場機会
      • 生物製剤の研究開発への投資の増加
      • バイオ医薬品パイプラインの堅調な成長

第4章 二重特異性抗体の世界市場産業分析

  • ポーターの5フォースモデル
    • 供給企業の交渉力
    • 買い手の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係
  • ポーターの5フォース影響分析
  • PEST分析
    • 政治
    • 経済
    • 社会
    • 技術
    • 環境
    • 法律
  • 主な投資機会
  • 主要成功戦略
  • COVID-19影響分析
  • 破壊的動向
  • 業界専門家の視点
  • アナリストの結論・提言

第5章 二重特異性抗体の世界市場：適応症別

  • 市場スナップショット
  • 二重特異性抗体の世界市場：適応症別、実績 - ポテンシャル分析
  • 二重特異性抗体の世界市場、適応症別推定・予測2020-2030年
  • 二重特異性抗体市場、サブセグメント分析
    • がん
    • 炎症性疾患・自己免疫疾患
    • その他

第6章 二重特異性抗体の世界市場：地域別分析

  • 主要国
  • 主な新興国
  • 二重特異性抗体市場、地域別市場スナップショット
  • 北米
    • 米国
      • 適応症別推定・予測、2020-2030年
    • カナダ
  • 欧州の二重特異性抗体市場スナップショット
    • 英国
    • ドイツ
    • フランス
    • スペイン
    • イタリア
    • その他欧州
  • アジア太平洋二重特異性抗体市場スナップショット
    • 中国
    • インド
    • 日本
    • オーストラリア
    • 韓国
    • その他アジア太平洋地域
  • ラテンアメリカの二重特異性抗体市場スナップショット
    • ブラジル
    • メキシコ
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • その他中東とアフリカ

第7章 競合情報

  • 主要企業のSWOT分析
  • 主要市場戦略
  • 企業プロファイル
    • Amgen, Inc.
      • 主要情報
      • 概要
      • 財務（データの入手可能性によります）
      • 製品概要
      • 最近の動向
    • Bayer AG
    • Dow Pharmaceutical Solutions
    • ImmunGene, Inc.
    • Immunocore Limited
    • Merck & Co., Inc.
    • Novartis AG
    • Pfizer, Inc.
    • F. Hoffmann-La Roche AG
    • Akeso, Inc.

第8章 調査プロセス

  • 調査プロセス
    • データマイニング
    • 分析
    • 市場推定
    • 検証
    • 出版
  • 調査属性
  • 調査前提条件
図表

LIST OF TABLES

  • TABLE 1. Global Bispecific Antibodies Market, report scope
  • TABLE 2. Global Bispecific Antibodies Market estimates & forecasts by Region 2020-2030 (USD Billion)
  • TABLE 3. Global Bispecific Antibodies Market estimates & forecasts by Indication 2020-2030 (USD Billion)
  • TABLE 4. Global Bispecific Antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 5. Global Bispecific Antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 6. Global Bispecific Antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 7. Global Bispecific Antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 8. Global Bispecific Antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 9. Global Bispecific Antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 10. Global Bispecific Antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 11. Global Bispecific Antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 12. Global Bispecific Antibodies Market by segment, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 13. Global Bispecific Antibodies Market by region, estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 14. U.S. Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 15. U.S. Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 16. U.S. Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 17. Canada Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 18. Canada Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 19. Canada Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 20. UK Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 21. UK Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 22. UK Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 23. Germany Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 24. Germany Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 25. Germany Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 26. France Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 27. France Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 28. France Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 29. Italy Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 30. Italy Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 31. Italy Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 32. Spain Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 33. Spain Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 34. Spain Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 35. RoE Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 36. RoE Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 37. RoE Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 38. China Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 39. China Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 40. China Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 41. India Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 42. India Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 43. India Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 44. Japan Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 45. Japan Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 46. Japan Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 47. South Korea Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 48. South Korea Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 49. South Korea Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 50. Australia Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 51. Australia Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 52. Australia Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 53. RoAPAC Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 54. RoAPAC Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 55. RoAPAC Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 56. Brazil Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 57. Brazil Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 58. Brazil Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 59. Mexico Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 60. Mexico Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 61. Mexico Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 62. RoLA Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 63. RoLA Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 64. RoLA Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 65. Saudi Arabia Bispecific Antibodies Market estimates & forecasts, 2020-2030 (USD Billion)
  • TABLE 66. South Africa Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 67. RoMEA Bispecific Antibodies Market estimates & forecasts by segment 2020-2030 (USD Billion)
  • TABLE 68. List of secondary sources, used in the study of global Bispecific Antibodies Market
  • TABLE 69. List of primary sources, used in the study of global Bispecific Antibodies Market
  • TABLE 70. Years considered for the study
  • TABLE 71. Exchange rates considered

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

LIST OF FIGURES

  • FIG 1. Global Bispecific Antibodies Market, research methodology
  • FIG 2. Global Bispecific Antibodies Market, Market estimation techniques
  • FIG 3. Global Market size estimates & forecast methods
  • FIG 4. Global Bispecific Antibodies Market, key trends 2022
  • FIG 5. Global Bispecific Antibodies Market, growth prospects 2023-2030
  • FIG 6. Global Bispecific Antibodies Market, porters 5 force model
  • FIG 7. Global Bispecific Antibodies Market, pest analysis
  • FIG 8. Global Bispecific Antibodies Market, value chain analysis
  • FIG 9. Global Bispecific Antibodies Market by segment, 2020 & 2030 (USD Billion)
  • FIG 10. Global Bispecific Antibodies Market by segment, 2020 & 2030 (USD Billion)
  • FIG 11. Global Bispecific Antibodies Market by segment, 2020 & 2030 (USD Billion)
  • FIG 12. Global Bispecific Antibodies Market by segment, 2020 & 2030 (USD Billion)
  • FIG 13. Global Bispecific Antibodies Market by segment, 2020 & 2030 (USD Billion)
  • FIG 14. Global Bispecific Antibodies Market, regional snapshot 2020 & 2030
  • FIG 15. North America Bispecific Antibodies Market 2020 & 2030 (USD Billion)
  • FIG 16. Europe Bispecific Antibodies Market 2020 & 2030 (USD Billion)
  • FIG 17. Asia pacific Bispecific Antibodies Market 2020 & 2030 (USD Billion)
  • FIG 18. Latin America Bispecific Antibodies Market 2020 & 2030 (USD Billion)
  • FIG 19. Middle East & Africa Bispecific Antibodies Market 2020 & 2030 (USD Billion)

List of tables and figures and dummy in nature, final lists may vary in the final deliverable

目次

Global Bispecific Antibodies Market is valued at approximately USD 5.73 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 44.0% over the forecast period 2023-2030. Bispecific antibodies are a class of therapeutic proteins created to attach to two distinct target molecules simultaneously. These antibodies have two separate antigen-binding sites that recognize a different antigen or receptor because of genetic engineering. Bispecific antibodies assemble these molecules, control their interactions, or transport medicinal substances to body parts by attaching two distinct targets. Bispecific antibodies provide several benefits compared to conventional monoclonal antibodies, which normally bind to a single target. They are used to target numerous disease-related pathways concurrently or to divert immune cells away from healthy tissue and toward tumor cells. The growing demand for targeted and personalized therapies, significant advancements in antibody engineering technologies, along with increasing collaborations and partnerships between local and international stakeholders are the key factors that are propelling the market demand during the estimated period.

In addition, the surge in the incidences of cancer cases is fueling the demand for a range of treatment alternatives including biospecific antibodies particularly those designed as immune checkpoint inhibitors or T cell engagers, which, in turn, accelerating the market growth across the world. According to The Global Cancer Observatory (GCO), in 2020, about 19.3 million new cases of cancer were reported worldwide and this number is expected to increase to 30.2 million in the year 2040. Biospecific antibodies redirect immune cells to attack tumor cells, leading to tumor regression and improved patient outcomes. Moreover, the increasing investment in biologics research and development, as well as the robust growth of the biopharmaceutical pipeline present various lucrative opportunities over the forecast years. However, the complex development and manufacturing and regulatory challenges are challenging the market growth throughout the forecast period of 2023-2030.

The key regions considered for the Global Bispecific Antibodies Market study include Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the increasing approval for several bispecific antibodies by regulatory bodies, growing investment in R&D activities, along with the presence of several leading market players. For instance, in October 2022, the first bispecific B-cell maturation antigen, teclistamab-cqyv (Tecvayli, Janssen Biotech, Inc.), received FDA approval. In addition, companies are increasingly participating in partnerships and collaborations to use complementary scientific expertise and technology to create bispecific antibodies. These partnerships promoted research and development initiatives, which has further accelerated market expansion. Europe is expected to grow at a substantial CAGR over the forecast years. The surging demand for bispecific antibodies, rising focus on technological advancements, as well as increasing collaborations and partnerships between local and international stakeholders are significantly propelling the market demand across the region.

Major market players included in this report are:

  • Amgen, Inc.
  • Bayer AG
  • Dow Pharmaceutical Solutions
  • ImmunGene, Inc.
  • Immunocore Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • F. Hoffmann-La Roche AG
  • Akeso, Inc.

Recent Developments in the Market:

  • In January 2023, Genentech, Inc., an American biotechnology corporation announced that the company has received FDA approval for the company's bispecific antibody that is specially designed for lymphoma. This approval enables the company to market their bispecific antibody across the region.
  • In May 2023, Genmab A/S unveiled that the U.S. Food and Drug Administration (FDA) has approved EPKINL (epcoritamab-bysp) as the first and only T-cell engaging bispecific antibody for the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma, following two or more lines of systemic therapy.

Global Bispecific Antibodies Market Report Scope:

  • Historical Data: 2020 - 2021
  • Base Year for Estimation: 2022
  • Forecast period: 2023-2030
  • Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
  • Segments Covered: Indication, Region
  • Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
  • Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.

By Indication:

  • Cancer
  • Inflammatory & Autoimmune Disorders
  • Others

By Region:

  • North America
  • U.S.
  • Canada
  • Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • ROE
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • RoAPAC
  • Latin America
  • Brazil
  • Mexico
  • Middle East & Africa
  • Saudi Arabia
  • South Africa
  • Rest of Middle East & Africa

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
    • 1.2.1. Bispecific Antibodies Market, by Region, 2020-2030 (USD Billion)
    • 1.2.2. Bispecific Antibodies Market, by Indication, 2020-2030 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Bispecific Antibodies Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Industry Evolution
    • 2.2.2. Scope of the Study
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Rates

Chapter 3. Global Bispecific Antibodies Market Dynamics

  • 3.1. Bispecific Antibodies Market Impact Analysis (2020-2030)
    • 3.1.1. Market Drivers
      • 3.1.1.1. Increasing demand for targeted and personalized therapies
      • 3.1.1.2. Surge in the incidences of cancer cases
    • 3.1.2. Market Challenges
      • 3.1.2.1. Complex development and manufacturing
      • 3.1.2.2. Regulatory challenges
    • 3.1.3. Market Opportunities
      • 3.1.3.1. Increasing investment in biologics research and development
      • 3.1.3.2. Robust growth of the biopharmaceutical pipeline

Chapter 4. Global Bispecific Antibodies Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
  • 4.2. Porter's 5 Force Impact Analysis
  • 4.3. PEST Analysis
    • 4.3.1. Political
    • 4.3.2. Economical
    • 4.3.3. Social
    • 4.3.4. Technological
    • 4.3.5. Environmental
    • 4.3.6. Legal
  • 4.4. Top investment opportunity
  • 4.5. Top winning strategies
  • 4.6. COVID-19 Impact Analysis
  • 4.7. Disruptive Trends
  • 4.8. Industry Expert Perspective
  • 4.9. Analyst Recommendation & Conclusion

Chapter 5. Global Bispecific Antibodies Market, by Indication

  • 5.1. Market Snapshot
  • 5.2. Global Bispecific Antibodies Market by Indication, Performance - Potential Analysis
  • 5.3. Global Bispecific Antibodies Market Estimates & Forecasts by Indication 2020-2030 (USD Billion)
  • 5.4. Bispecific Antibodies Market, Sub Segment Analysis
    • 5.4.1. Cancer
    • 5.4.2. Inflammatory & Autoimmune Disorders
    • 5.4.3. Others

Chapter 6. Global Bispecific Antibodies Market, Regional Analysis

  • 6.1. Top Leading Countries
  • 6.2. Top Emerging Countries
  • 6.3. Bispecific Antibodies Market, Regional Market Snapshot
  • 6.4. North America Bispecific Antibodies Market
    • 6.4.1. U.S. Bispecific Antibodies Market
      • 6.4.1.1. Indication breakdown estimates & forecasts, 2020-2030
    • 6.4.2. Canada Bispecific Antibodies Market
  • 6.5. Europe Bispecific Antibodies Market Snapshot
    • 6.5.1. U.K. Bispecific Antibodies Market
    • 6.5.2. Germany Bispecific Antibodies Market
    • 6.5.3. France Bispecific Antibodies Market
    • 6.5.4. Spain Bispecific Antibodies Market
    • 6.5.5. Italy Bispecific Antibodies Market
    • 6.5.6. Rest of Europe Bispecific Antibodies Market
  • 6.6. Asia-Pacific Bispecific Antibodies Market Snapshot
    • 6.6.1. China Bispecific Antibodies Market
    • 6.6.2. India Bispecific Antibodies Market
    • 6.6.3. Japan Bispecific Antibodies Market
    • 6.6.4. Australia Bispecific Antibodies Market
    • 6.6.5. South Korea Bispecific Antibodies Market
    • 6.6.6. Rest of Asia Pacific Bispecific Antibodies Market
  • 6.7. Latin America Bispecific Antibodies Market Snapshot
    • 6.7.1. Brazil Bispecific Antibodies Market
    • 6.7.2. Mexico Bispecific Antibodies Market
  • 6.8. Middle East & Africa Bispecific Antibodies Market
    • 6.8.1. Saudi Arabia Bispecific Antibodies Market
    • 6.8.2. South Africa Bispecific Antibodies Market
    • 6.8.3. Rest of Middle East & Africa Bispecific Antibodies Market

Chapter 7. Competitive Intelligence

  • 7.1. Key Company SWOT Analysis
    • 7.1.1. Company 1
    • 7.1.2. Company 2
    • 7.1.3. Company 3
  • 7.2. Top Market Strategies
  • 7.3. Company Profiles
    • 7.3.1. Amgen, Inc.
      • 7.3.1.1. Key Information
      • 7.3.1.2. Overview
      • 7.3.1.3. Financial (Subject to Data Availability)
      • 7.3.1.4. Product Summary
      • 7.3.1.5. Recent Developments
    • 7.3.2. Bayer AG
    • 7.3.3. Dow Pharmaceutical Solutions
    • 7.3.4. ImmunGene, Inc.
    • 7.3.5. Immunocore Limited
    • 7.3.6. Merck & Co., Inc.
    • 7.3.7. Novartis AG
    • 7.3.8. Pfizer, Inc.
    • 7.3.9. F. Hoffmann-La Roche AG
    • 7.3.10. Akeso, Inc.

Chapter 8. Research Process

  • 8.1. Research Process
    • 8.1.1. Data Mining
    • 8.1.2. Analysis
    • 8.1.3. Market Estimation
    • 8.1.4. Validation
    • 8.1.5. Publishing
  • 8.2. Research Attributes
  • 8.3. Research Assumption